Neurology
-
Randomized Controlled Trial Clinical Trial
Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease.
To investigate if a central cholinesterase inhibitor will reduce falling frequency in subjects with Parkinson disease (PD) with advanced postural instability. ⋯ This study provides Class II evidence that donepezil (maximum 10 mg per day) significantly reduced the number of falls in patients with PD (0.13 falls/day, SEM = 0.03) than when taking placebo (0.25 falls/day, SEM = 0.08, p = 0.049).